Xenetic Biosciences, Inc. (XBIO) Issues Quarterly Earnings Results
Xenetic Biosciences, Inc. (NASDAQ:XBIO) released its quarterly earnings data on Wednesday. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.03), Bloomberg Earnings reports.
Shares of Xenetic Biosciences (NASDAQ XBIO) opened at $2.42 on Friday. Xenetic Biosciences has a 52-week low of $1.75 and a 52-week high of $5.90.
Separately, Zacks Investment Research raised shares of Xenetic Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Saturday, September 16th.
About Xenetic Biosciences
Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.
Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.